Predict your next investment

Corporation
formosalab.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

2

About Formosa Laboratories

Formosa Laboratories (台耀化学 / 台耀化學) (TPE: 4746) is a biotechnology and pharmaceutical company focused on research and development for bulk pharmaceutical chemical production. Formosa's major API products include Vitamin D derivatives (Alfacalcidol, Calcitriol, Calcipotriol, Doxercalciferol, and Paricalcitol), Balsalazide, Benzonatate, Capsaicin, Colesevelam, Gadodiamide, Flupentixol, Melitracen, Meprobamate, Montelukast, Mycophenolate Mofetil, Sevelamer (HCl and Carbonate), and Taltirelin.

Formosa Laboratories Headquarter Location

36 Hoping Street Louchu

Taoyuan, 33842,

Taiwan

+886-3-324-0895

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Formosa Laboratories News

HCmed, Formosa Labs and Formosa Pharma Form Inhalation CDMO

Mar 10, 2022

HCmed, Formosa Labs and Formosa Pharma Form Inhalation CDMO HCmed, Formosa Labs and Formosa Pharma Form Inhalation CDMO The three parties are expected to become a one-stop-shop in the biopharmaceutical industry as a full-service CDMO. 03.10.22 HCmed Innovations  has formed an alliance with Formosa Laboratories and Formosa Pharmaceuticals to expand its business in the inhalation treatment field, providing contract development and manufacturing services. By integrating HCmed's vibrating mesh nebulizers, Formosa Laboratories' drug development and manufacturing capabilities and Formosa Pharmaceuticals' APNT nanotechnology platform, the three parties are expected to become a one-stop-shop in the biopharmaceutical industry as a full-service contract development and manufacturing organization (CDMO). According to statistics, the global inhalation drug market reached $25 billion in 2020. In addition, as the COVID-19 pandemic has driven demand for respiratory treatment drugs during the past two years, the demand for developing respiratory drugs has also grown stronger, prompting several well-known global pharmaceutical companies to take the initiative to incorporate HCmed's proprietary mesh technology into the development of their inhaled products. "Currently, global CDMO companies that focus on developing drug-device combination products cannot only provide their pharma partners with a platform to deliver drugs, but also with integrated services that extend to drug development, mass production and product packaging," said Jason Cheng, CEO of HCmed. "Through these services, the combination product development time can be shortened and costs can be reduced. With this objective, HCmed, Formosa Laboratories and Formosa Pharmaceuticals aim to provide a fully integrated CDMO service platform, which is expected to further expand the companies' business, providing fully-integrated solutions and creating long-term win-win relationships." The companies share similar visions on the development of their CDMO business. The collaboration between the parties signifies the joining of forces between three key players in the biotechnology and high-end medical device industries in the respiratory drug market. With Formosa Pharmaceuticals' nanotechnology platform, Formosa Laboratories' development and production experience of APIs, ADCs and injections, and HCmed's technology in developing customized mesh nebulizers, the parties aspire to provide an all-round service across the full development process, including early drug development, clinical trials execution, mass production and product launch. This collaboration is expected to increase the number of CDMO orders, deepen customer relationships and contribute to revenue increase. 03.09.22 02.10.22 01.25.22 01.06.22 11.08.21 11.05.21 10.26.21 10.25.21 10.21.21 09.24.21 09.23.21 08.17.21 08.04.21 07.22.21 07.12.21

Formosa Laboratories Investments

1 Investments

Formosa Laboratories has made 1 investments. Their latest investment was in TOT BIOPHARM as part of their Series A on March 3, 2016.

CBI Logo

Formosa Laboratories Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/1/2016

Series A

TOT BIOPHARM

$24M

Yes

2

Date

3/1/2016

Round

Series A

Company

TOT BIOPHARM

Amount

$24M

New?

Yes

Co-Investors

Sources

2

Formosa Laboratories Portfolio Exits

1 Portfolio Exit

Formosa Laboratories has 1 portfolio exit. Their latest portfolio exit was TOT BIOPHARM on November 08, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2019

IPO

$99M

3

Date

11/8/2019

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

3

Formosa Laboratories Partners & Customers

2 Partners and customers

Formosa Laboratories has 2 strategic partners and customers. Formosa Laboratories recently partnered with Huichuang Medical on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/7/2022

Partner

China

HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs

By integrating HCmed 's vibrating mesh nebulizers , Formosa Laboratories , Inc. ' drug development and manufacturing capabilities , and Formosa Pharmaceuticals ' APNT nanotechnology platform , the three parties are expected to become a one-stop shop in the biopharmaceutical industry as a full-service contract development and manufacturing organization .

2

3/6/2022

Partner

Subscribe to see more

Subscribe to see more

10

Date

3/7/2022

3/6/2022

Type

Partner

Partner

Business Partner

Country

China

News Snippet

HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs

By integrating HCmed 's vibrating mesh nebulizers , Formosa Laboratories , Inc. ' drug development and manufacturing capabilities , and Formosa Pharmaceuticals ' APNT nanotechnology platform , the three parties are expected to become a one-stop shop in the biopharmaceutical industry as a full-service contract development and manufacturing organization .

Subscribe to see more

Subscribe to see more

Sources

2

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.